Individuals should continue to receive asthma care and take asthma medications during the pandemic.
Although it has become widely accepted that COPD encompasses a range of phenotypes, the development of a precision medicine approach has been slow.
Asthma and chronic obstructive pulmonary disease (COPD) do not appear to increase the risk of mortality in patients with COVID-19.
In adults with COPD, long-term exposure to PM2.5 was associated with an increased risk for cardiovascular mortality.
Indoor mold exposure and the presence of anti-Aspergillus antibodies may be linked to worsened lung function during exacerbations in COPD.
While the ACA effectively reversed coverage losses for patients with airway disease, neither care affordability nor disparities improved for these patients.
Electronic cigarette (e-cigarette) use may be associated with an increased risk of chronic obstructive pulmonary disease (COPD).
In patients with COPD, lockdown for coronavirus disease 2019 (COVID-19) was associated with a reduction in exacerbations and an improvement in symptoms.
Duration-dependent beneficial effects of metformin, sulfonylurea, and thiazolidinedione use on COPD exacerbation have been observed in patients with COPD and diabetes.
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate may reduce the risk of death compared with glycopyrrolate/formoterol fumarate in patients with COPD.
The adjusted rate of decline in predose trough FEV1 during 52 weeks in theResearchers used a substudy of the Phase 3 ETHOS study to evaluate lung function decline in patients with inhaled corticosteroid-containing therapies vs glycopyrrolate/formoterol fumarate metered dose inhaler.
Once-daily revefenacin when administered via a jet nebulizer with formoterol was well tolerated and associated with greater lung function response compared with formoterol alone in patients with COPD.
Chronic obstructive pulmonary disease may be associated with higher rates of mortality in patients with coronavirus disease 2019.
Implementation of the Hospital Readmission Reduction Program was associated with a decrease in 30-day readmissions in patients with COPD following their hospital discharge.
Recommendations are presented for the use of noninvasive ventilation for patients with COPD and chronic hypercapnia in an American Thoracic Society clinical practice guideline.
The 12-month history of acute exacerbations used to guide most COPD treatment relies on an unstable frequent exacerbator phenotype.
Treatment with dupilumab led to significant improvements in lung function by 16 weeks and up to 24 weeks in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma plus clinical features of COPD.
The FDA has approved Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate; AstraZeneca) for the maintenance treatment of chronic obstructive pulmonary disease.
Triple therapy, including glucocorticoid at either of 2 dose levels, is beneficial for moderate-to-very severe chronic obstructive pulmonary disease.
Preemptive, patient-specific electronic messages from pulmonologists to primary care physicians improved guideline concordant care in COPD.